The N=1 is necessarily concerning considering the

The N=1 is necessarily concerning considering the trial just started, but it makes the findings subject to scrutiny. But what’s different about leronlimab and cancer is that the endpoints can be proven though a verified lab result and radiologic findings. These aren’t subjective endpoints like pain level, cognitive abilities, effect on activities of daily living, etc, but indisputable scientific findings.

I suspect CYDY is already doing so, but NP needs to enroll as many breast cancer patients as possible and to keep the flow of patients coming until results are clear and/or leronlimab is approved by the FDA for mTNBC.